MA29563B1 - Composes organiques - Google Patents

Composes organiques

Info

Publication number
MA29563B1
MA29563B1 MA30506A MA30506A MA29563B1 MA 29563 B1 MA29563 B1 MA 29563B1 MA 30506 A MA30506 A MA 30506A MA 30506 A MA30506 A MA 30506A MA 29563 B1 MA29563 B1 MA 29563B1
Authority
MA
Morocco
Prior art keywords
new
compound represented
organic compounds
formula
aliskirene
Prior art date
Application number
MA30506A
Other languages
English (en)
Inventor
Stuart John Mickel
Gottfried Sedelmeier
Hans Hirt
Frank Schaefer
Michael Foulkes
Walter Prikoszovich
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA29563B1 publication Critical patent/MA29563B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

COL'INVENTION CONCERNE UNE NOUVELLE MÉTHODE, DE NOUVELLES ÉTAPES DE TRAITEMENT ET DE NOUVEAUX INTERMÉDIAIRES UTILES DANS LA SYNTHÈSE DE COMPOSÉS ACTIFS SUR LE PLAN PHARMACEUTIQUE, EN PARTICULIER, DES INHIBITEURS DE RÉNINE, TELS QU'ALISKIRÈNE. ELLE CONCERNE, ENTRE AUTRES, UNE MÉTHODE SERVANT À PRÉPARER UN COMPOSÉ REPRÉSENTÉ PAR LA FORMULE III, DANS LAQUELLE R, R1, R2, R3 ET PG SONT ANALOGUES À LEUR DÉFINITION DANS LA SPÉCIFICATION, OU UN DE LEURS SELS, LADITE PRÉPARATION CONSISTANT À EFFECTUER LA RÉACTION D'UN COMPOSÉ REPRÉSENTÉ PAR LA FORMULE (I) AVEC UN RÉACTIF CAPABLE DE TRANSFORMER HYDROXY EN X, X ÉTANT, PAR EXEMPLE, UN GROUPE PARTANT.
MA30506A 2005-06-08 2007-12-26 Composes organiques MA29563B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0511686.8A GB0511686D0 (en) 2005-06-08 2005-06-08 Organic compounds

Publications (1)

Publication Number Publication Date
MA29563B1 true MA29563B1 (fr) 2008-06-02

Family

ID=34835327

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30506A MA29563B1 (fr) 2005-06-08 2007-12-26 Composes organiques

Country Status (24)

Country Link
US (2) US7767831B2 (fr)
EP (2) EP2080754A3 (fr)
JP (2) JP2008542415A (fr)
KR (1) KR20080014011A (fr)
CN (1) CN101193860B (fr)
AR (1) AR054374A1 (fr)
AU (1) AU2006256938B2 (fr)
BR (1) BRPI0611919A2 (fr)
CA (1) CA2608575A1 (fr)
EC (1) ECSP077986A (fr)
GB (1) GB0511686D0 (fr)
GT (1) GT200600208A (fr)
IL (1) IL187004A0 (fr)
MA (1) MA29563B1 (fr)
MX (1) MX2007015418A (fr)
NO (1) NO20080080L (fr)
NZ (2) NZ562889A (fr)
PE (2) PE20070075A1 (fr)
RU (1) RU2418785C2 (fr)
SG (1) SG155209A1 (fr)
TN (1) TNSN07465A1 (fr)
TW (1) TW200716544A (fr)
WO (1) WO2006131304A2 (fr)
ZA (1) ZA200709076B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0521083D0 (en) 2005-10-17 2005-11-23 Novartis Ag Organic compounds
DE102007049039A1 (de) 2007-10-11 2009-04-16 Reuter Chemischer Apparatebau Kg Verfahren zur Herstellung von 8-Hydrazino-8-Aryl-Octanoylderivaten und deren Verwendung
EP2062874B1 (fr) 2007-11-20 2014-12-17 KRKA, tovarna zdravil, d.d., Novo mesto Procédé et intermédiaires pour la préparation d'aliskiren
PT2225200E (pt) 2007-12-24 2014-01-21 Dsm Ip Assets Bv Síntese convergente de inibidores da renina e intermediários úteis nesta
SI2189442T1 (sl) 2008-11-20 2015-03-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek in intermediati za pripravo aliskirena
IN2012DN00862A (fr) * 2009-08-11 2015-07-10 Novartis Ag
WO2011051853A1 (fr) 2009-10-29 2011-05-05 CarboDesign LLC Procédé de production de dérivés d'acides 8-aryloctanoïques énantiomèrement purs tels que l'aliskiren
EP2523934A1 (fr) * 2010-02-10 2012-11-21 Ratiopharm GmbH Sels d'aliskirène
US8703976B2 (en) 2011-10-02 2014-04-22 Milan Soukup Manufacturing process for 8-aryloctanoic acids such as Aliskiren
CN111423325A (zh) * 2020-04-26 2020-07-17 江苏凯迪恩医药科技有限公司 基于蒽醌类药物的双醋瑞因合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4570108A (en) * 1982-07-06 1986-02-11 Stroede Aake Protection device for electrical incandescent lamps
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
US5659065A (en) 1994-04-18 1997-08-19 Novartis Corporation Alpha-aminoalkanoic acids and reduction products
US5606078A (en) 1994-04-18 1997-02-25 Ciba-Geigy Corporation 3,5-Disubstituted tetrahydrofuran-2-ones
CA2121898A1 (fr) * 1994-04-21 1995-10-22 Stephen Hanessian Synthese de prototypes d'inhibiteurs de la renine
IT1292426B1 (it) * 1997-06-27 1999-02-08 Nicox Sa Sali nitrati di ace-inibitori
JP2005231999A (ja) * 2000-03-08 2005-09-02 Banyu Pharmaceut Co Ltd カルバペネム誘導体の製造方法
EP1296935B1 (fr) 2000-07-05 2009-03-25 Speedel Pharma AG Procede de preparation d'amide d'octanoyl substitues
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
EP1215201B1 (fr) * 2000-12-14 2006-10-18 Speedel Pharma AG Procédé pour la préparation d'aryloctanoylamides
GB0419361D0 (en) 2004-08-31 2004-10-06 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
TNSN07465A1 (en) 2009-03-17
GB0511686D0 (en) 2005-07-13
WO2006131304A3 (fr) 2007-07-19
CN101193860B (zh) 2013-01-02
JP2008542415A (ja) 2008-11-27
BRPI0611919A2 (pt) 2010-10-05
NZ562889A (en) 2011-11-25
WO2006131304A2 (fr) 2006-12-14
CN101193860A (zh) 2008-06-04
US7767831B2 (en) 2010-08-03
AU2006256938B2 (en) 2009-12-17
JP2013028607A (ja) 2013-02-07
EP1896411A2 (fr) 2008-03-12
KR20080014011A (ko) 2008-02-13
AU2006256938A1 (en) 2006-12-14
SG155209A1 (en) 2009-09-30
CA2608575A1 (fr) 2006-12-14
NZ591010A (en) 2012-06-29
GT200600208A (es) 2007-03-28
NO20080080L (no) 2008-01-04
RU2418785C2 (ru) 2011-05-20
MX2007015418A (es) 2008-02-21
ECSP077986A (es) 2008-01-23
IL187004A0 (en) 2008-02-09
EP2080754A3 (fr) 2010-06-02
PE20070075A1 (es) 2007-03-16
PE20091359A1 (es) 2009-10-13
EP2080754A2 (fr) 2009-07-22
RU2007148226A (ru) 2009-07-20
AR054374A1 (es) 2007-06-20
US20080207921A1 (en) 2008-08-28
US20100274027A1 (en) 2010-10-28
ZA200709076B (en) 2008-10-29
TW200716544A (en) 2007-05-01

Similar Documents

Publication Publication Date Title
TN2009000138A1 (fr) Biaryl-ether-urees
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA27990A1 (fr) Derives de piperazine pour le traitement d'infections par le vih
MA27725A1 (fr) Benzopyrannes utiles pour le traitement d'etats inflammatoires
TNSN07349A1 (fr) Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur
TNSN08196A1 (fr) Derives de pyrazine
MA63501A1 (fr) Dérivés d'urée pouvant être utilisés pour traiter le cancer
MA32120B1 (fr) Nouveaux composes chimiques
TNSN08270A1 (fr) Dérivés pyrimidiques destinés à traiter une croissance cellulaire anormale
MA29311B1 (fr) Derives d'isoxazolines et son nouveau procede de production
MA30784B1 (fr) Derives phenyliques et utilisation de ceux-ci en tant qu'immunomodulateurs.
TN2009000428A1 (fr) Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale
MA31466B1 (fr) Derives de benzimidazole
MA34359B1 (fr) Dérivés de carbamate d'hexafluoroisopropyle, leur préparation et leur application thérapeutique
TNSN07022A1 (fr) Derives de pyridine
MA35422B1 (fr) Imidazopyridazines amino-substituees
MA29411B1 (fr) 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa
MA30912B1 (fr) Nouveaux derives de phenylsulfamoyl-benzamide en tant qu'antagonistes de la bradykinine
MA29160B1 (fr) Derives de triazole substitues, servant d'antagonistes d'ocytocine
MA63458B1 (fr) Nouveaux dérivés de sulfonamide pyrimidin-2-yl
MA30916B1 (fr) Nouveaux derives de benzamide en tant qu'antagonistes de bradykinine
MA31116B1 (fr) Procede de synthese de derives de l'acide 3-amino-tetrahydro-furan-3-carboxylique et utilisation de ceux-ci en tant que medicaments
MA63885A1 (fr) Composés inhibant l'isoforme alpha de pi3k et méthodes de traitement du cancer
MA29852B1 (fr) Synthese d'inhibiteurs de la renine impliquant une reaction de cycloaddition
Juang et al. Design, synthesis and biological evaluations of niclosamide analogues against SARS-CoV-2